References
- Al-dabbagh S. G., Idle J. R., Smith R. L. Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strains. Journal of Pharmacy and Pharmacology 1981; 33: 161–164
- Boobis A. R., Seddon C. E., Davies D. S. Bufuralol 1′-hydroxylase activity of the rat. Strain differences and the effects of inhibitors. Biochemical Pharmacology 1986; 35: 2961–2965
- Brinn R., Brøsen K., Gram L. F., Haghfelt T., Otton S. V. Sparteine oxidation is practically abolished in quinidine-treated patients. British Journal of Clinical Pharmacology 1986; 22: 194–197
- Guengerich F. P., Müller-Enoch D., Blair I. A. Oxidation of quinidine by human liver cytochrome P-450. Molecular Pharmacology 1986; 30: 287–295
- Hawes E. M., Roy S. D., McKay G., Midha K. K. Methoxyphenamine O-demethylase and 5-hydroxylase: A GLC-ECD assay to study their activities and their inhibition by debrisoquine and sparteine. Pharmacology and Therapeutics 1987; 33: 73–77
- Inaba T., Jurima M., Mahon W. A., Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450: Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metabolism and Disposition 1985; 13: 443–448
- Inaba T., Tynedale R. E., Mahon W. A. Quindine: potent inhibition of sparteine and debrisoquine oxidatio in vivo. British Journal of Clinical Pharmacology 1986; 22: 199–200
- Inoue T., Niwaguchi T., Emoto M. Studies of metabolism of methamphentamine analogs. III. Urinary excretion of methoxyphenamine and its metabolites. Kagaku Keisatsu Kenkyosho Hokoku, Hokagaku Hen 1980; 33: 33–37
- Jacqz E., Hall S. D., Branch R. Genetically determined polymorphisms in drug oxidation. Hepatology 1986; 6: 1020–1032
- Kalow W. Genetic variation in the human cytochrome P-450 system. European Journal of Clinical Pharmacology 1987; 31: 633–641
- Leemann T., Dayer P., Meyer U. A. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. European Journal of Clinical Pharmacology 1986; 29: 739–741
- Lennard M. S., Tucker G. T., Silas J. H., Woods H. F. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 1986; 16: 435–447
- Mc Kay G., Cooper J. K., Hawes E. M., Roy S. D., Midha K. K. Identification of new secondary metabolites of methoxyphenamine in man. Xenobiotica 1983; 13: 257–264
- Meyer U. A., Gut J., Kronbach T., Skoda C., Meier U. T., Catin T. The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 1986; 16: 449–464
- Midha K. K., Cooper J. K., McGilveray I. J., Coutts R. T., Dawe R. Metabolism of methoxyphenamine in man and in monkey. Drug Metabolism and Disposition 1976; 4: 568–576
- Mikus G., Ha H. R., Vozeh S., Zekorn C., Follath F., Eichelbaum M. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine. European Journal of Clinical Pharmacology 1986; 31: 69–72
- Otton S. V., Inaba T., Kalow W. Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sciences 1984; 34: 73–80
- Roy S. D., Hawes E. M., McKay G., Korchinski E. D., Midha K. K. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquine. Clinical Pharmacology and Therapeutics 1985a; 38: 128–133
- Roy S. D., Hawes E. M., McKay G., Hubbard J. W., Midha K. K. Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes. Canadian Journal of Physiology and Pharmacology 1985b; 63: 778–781
- Roy S. D., Hawes E. M., Midha K. K. Influence of urinary pH on the disposition of methoxyphenamine and three metabolites in humans. Journal of Pharmaceutical Sciences 1987; 76: 427–432
- Speirs C. J., Murray S., Boobis A. R., Seddon C. E., Davies D. S. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. British Journal of Clinical Pharmacology 1986; 22: 739–743
- Von Bahr C., Spina E., Birgersson C., Ericsson Ö., Göransson M., Henthorn T., Sjöqvist F. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochemical Pharmacology 1985; 34: 2501–2505